Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25469619 | 0.84 | GRM4 (0.36) | GRM4KDM4ELMNAALDH1A1POLB | |
| SCHEMBL803084 | 0.82 | SYK (0.39) | GRM4KDM4ELMNAAAK1ALDH1A1 | |
| SCHEMBL10193126 | 0.78 | GRM4 (0.35) | GRM4KDM4ELMNAAAK1ALDH1A1 | |
| SCHEMBL28203328 | 0.78 | HCRTR1 (0.35) | GRM4KDM4ELMNAAAK1 | |
| SCHEMBL20909663 | 0.78 | GRM4 (0.35) | GRM4KDM4ELMNAAAK1ALDH1A1 | |
| SCHEMBL19670056 | 0.77 | ADORA2A (0.33) | — | |
| SCHEMBL171691 | 0.76 | ADRB1 (0.43) | GRM4KDM4E | |
| SCHEMBL20350390 | 0.75 | GRM4 (0.33) | GRM4KDM4ELMNAAAK1 | |
| SCHEMBL16454353 | 0.74 | JAK2 (0.43) | GRM4KDM4ELMNAAAK1 | |
| SCHEMBL28173201 | 0.72 | SORT1 (0.36) | GRM4KDM4ELMNAAAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | GRM4 4053/4885KDM4E 2241/4885LMNA 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.